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Background: Several studies have shown that exposure to benzene is associated to menstrual disorders, miscarriages
and other disorders of the reproductive system. We performed an observational prospective pilot study to evaluate if
levels of benzene in follicular fluid were correlated with response to controlled ovarian stimulation.
Method: Thirty-four normogonadotrophic women undergoing IVF were enrolled. Intra-follicular benzene levels were
evaluated by chromatography/mass spectrometry. Based on median benzene level, we divided the study population in
two groups: Group A with a “low” intra-follicular benzene concentration (n = 19, benzene <0.54 ng/mL) and Group B
with a “high” intra-follicular benzene concentration (n = 15, benzene≥ 0.54 ng/mL). The ovarian response to
gonadotrophins and the outcome of IVF were analyzed in the two groups.
Results: The two groups did not differ in terms of demographic or anthropometric characteristics. Group B had
significantly higher basal FSH levels, lower estradiol peak concentration, and fewer oocytes retrieved and embryos
transferred (p < 0.05). Number of gonadotrophin vials, length of controlled ovarian stimulation and ongoing pregnancy
rate were similar in the two groups.
Conclusion: In conclusion, ovarian response to endogenous and exogenous gonadotrophins appeared to be
influenced by intra-follicular benzene levels.
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Several lines of evidence suggest that exposure to environ-
mental contaminants is involved in the pathobiology of
adverse reproductive health effects, including decreased
semen quality, sub-fertility, reduced fetal growth and pre-
term birth [1-6]. Developmental abnormalities of the male
reproductive tract were also reported [7]. Among environ-
mental contaminants, polychlorinated biphenyls (PCBs),
hexachlorobenzene (HCB), trichloro-bis-chlorophenyl-
ethane (DDT) and benzene seem to play a relevant role in
adverse reproductive health effects [8].* Correspondence: confale@hotmail.it
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unless otherwise stated.Benzene is a volatile, colorless, highly flammable liquid
[9]. Today, most benzene (98%) is commercially derived
from petrochemical and petroleum-refining industries.
Benzene is a by-product of such combustion processes
as forest fires and the burning of wood, garbage, organic
wastes and cigarettes [10-13]. Benzene is ubiquitous in
the environment, having been measured in air, water,
and human biological samples [13-17].
The major sources of benzene exposure are tobacco
smoke, automobile service stations, exhaust from motor
vehicles and industrial emissions. About half the exposure
to benzene in the United States results from smoking to-
bacco or from exposure to tobacco smoke [9]. The average
smoker (32 cigarettes per day) takes in about 1.8 mg of
benzene per day. This amount is about 10 times the aver-
age daily intake of benzene by non-smokers [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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exposure to high concentrations of benzene negatively
affects reproduction. Specifically, benzene exposure in
the workplace was associated with high rates of func-
tional disturbances of the menstrual cycle [18], prema-
ture interruptions of pregnancy [19,20] and reduction in
birth weight and head circumference during pregnancy
and at birth [21].
Notwithstanding the evidence linking benzene expos-
ure to negative reproductive health effects, the patho-
genesis of adverse reproductive outcomes and benzene
exposure has not yet been explored. In this context,
in vitro fertilization (IVF) is a good in vivo model with
which to evaluate directly the effects exerted by benzene
on each step of the reproductive process.
The aim of this pilot study was to preliminarily evalu-
ate the relationship between concentrations of benzene
in the follicular fluid (FF) and the outcome of IVF/ICSI
(intracytoplasmic sperm injection) cycles.
Methods
Thirty-four consecutive women attending the IVF pro-
gram at the Reproductive Medicine Unit of the University
of Naples “Federico II” were prospectively enrolled from
November 2011 to January 2012. Institutional Review
Board approval was not required for the present study due
to the observational design. No adjunctive procedure has
been introduced and all the IVF/ICSI cycles were per-
formed according to routine clinical practice.
A comprehensive written consent form was signed by
all participants before enrolment. They also completed a
short questionnaire regarding their occupation, place of
residence, smoking and driving habits. Only normogona-
dotrophic patients aged < 38 years with menstrual cycles
ranging from 24 to 35 days (intra-individual variability ±
3 days), body mass index (BMI) > 20 and < 28.0 kg/m2
and hysteroscopic evidence of a normal uterine cavity
within the last 6 months were included.
Women with diabetes mellitus, hypopituitarism, hyper-
prolactinemia, luteal insufficiency, polycystic ovarian
syndrome [22], polycystic ovaries, endometriosis, dysthyr-
oidism, chronic inflammatory diseases, autoimmune dis-
orders, chromosomal abnormalities or genetic diseases
were excluded.
All patients underwent a gonadotrophin releasing
hormone-agonist (GnRH-a) long down-regulation proto-
col with the administration of GnRH-a triptorelin, at the
daily dose of 0.1 mg s.c., from the mid-luteal phase for
12–20 days (Decapeptyl 0.1 mg; Ipsen S.p.A., Milan,
Italy). Ovarian stimulation was performed with recom-
binant follicular stimulating hormone (FSH) (Gonal F,
Merck Serono S.p.A., Bari, Italy), using an individualized
dose of between 150 IU and 225 IU s.c. daily according
to baseline age, BMI and FSH levels. Ovarian responsewas monitored by ultrasound examination starting on
day 5 of stimulation and the dose of recombinant FSH
was adjusted if necessary. The ovulatory dose of human
chorionic gonadotrophin (HCG), 10,000 IU (Gonasi HP;
IBSA Farmaceutici Italia Srl, Lodi, Italy) was adminis-
tered when at least three follicles reached a mean diam-
eter of 17 mm. Oocytes were retrieved 35 h after HCG
prescription.
Oocytes were washed immediately after retrieval in
in vitro fertilisation medium (IVF Medicult, Copenhagen,
Denmark) and cultured before IVF/ICSI. Fertilisation was
checked 16–20 h after insemination, which was confirmed
by the presence of two pronuclei. Zygotes were then
washed and transferred to fresh media for embryo culture.
No embryo selection was performed before transfer.
Therefore, only embryos obtained after all IVF procedures
were implanted. According to Italian legislation our policy
was to limit the number of oocytes to be fertilised. Given
that young and eumenorrohoic women (good prognosis)
were enrolled, 3 oocytes were fertilised in all of them with
no case of embryo freezing.
Luteal phase support was given vaginally in the form of
400 mg micronized progesterone (Prometrium; Rottapharm
S.p.A., Milan, Italy) twice daily, starting on the day after
oocyte retrieval and continuing until the day of the preg-
nancy test (i.e. day 12 after embryo transfer). The viability
of pregnancy was confirmed by transvaginal ultrasound
scan at 10 weeks.
Benzene chromatographic/spectrometric assay
After isolation of oocytes, FF was pooled and stored
(−80°C) until analysis. The concentration of benzene in
FF samples was measured as follows. Samples were
thawed at room temperature and the whole sample (ran-
ging from 500 μl to 2 ml) was transferred into 10 ml
vials containing 1 g NaCl. Vials were sealed with sili-
cone/teflon-lined septa, and 50 μl of a 29.6 ng/ml hexa-
deuterated benzene (C6D6, internal standard) aqueous
solution was added to each sample to obtain a constant
internal standard amount of 1.48 ng. Hexadeuterated
benzene, sodium chloride, 10 ml vials and silicone/teflon
lined (0.1-mm thick coating) septa, “superior standard”,
were from Carlo Erba (Milan, Italy). Solid phase microex-
traction (SPME) fibers, (fused-silica fibers 10 mm long,
coated with an 85-μm-thick layer of carboxen/polydi-
methylsiloxane) and fiber holders were from Supelco
(Bellafonte, PA, USA). Samples were analyzed with a head
space/solid phase microextraction (HS/SPME) method
and gas chromatography coupled with mass spectrome-
try (GC-MS). We used the Gas Chromatograph-Single
Quadrupole Mass Spectrometer “HRGC 8000 series/
VOYAGER” (Fisons Instruments, Ipswich, UK), equipped
with a split/splitless injector (0.75 mm i.d. inlet liner for
SPME [Supelco, Bellafonte, PA, USA]) and a Zebron 624
Table 1 The main indications, basal characteristics and







Male factor 7 (36.8%) 10 (66.6%) 0.16
Severe OAT 6 8
Mild OAT 1 2
Female factor 10 (52.6%) 5 (33.3%) 0.31
Tubal factor 7 4
Repeated abortions 1 0
Others female factors 2 1
Idiopathic factor 2 (10.5%) 0 0.49
Basal characteristics
Age (years) 31 ± 4.7 32 ± 4.8 0.74
BMI (kg/m2) 24.0 ± 3.5 25.3 ± 2.2 0.85
Intra-follicular benzene
(ng/mL)
0.15 ± 0.2 1.5 ± 1.25 0.001
Baseline FSH (IU/L) 5.8 ± 1.1 11.3 ± 4.2 0.003
Baseline LH (IU/L) 3.9 ± 1.6 8.2 ± 2.5 0.07
IVF/ICSI outcome
Baseline E2 (pg/mL) 38.9 ± 16.1 38.4 ± 18.3 0.55
E2 peak (pg/mL) 1836.65 ± 661.9 1328.8 ± 493.0 0.008
Days of stimulation 13.2 ± 2.7 13.4 ± 2.6 0.75
Gonadotrophin vials 33.3 ± 15.2 32.65 ± 13.8 0.59
Oocytes retrieved 7.4 ± 2.5 6.6 ± 2.85 0.01
Embryos transferred 2.6 ± 0.4 2.3 ± 0.6 0.04
Ongoing pregnancy rate† 4 (21%) 4 (28%) 0.89
Data reported as mean ± SD or percentage [†n (%)].
BMI, body mass index, FSH, follicle-stimulating hormone; LH, luteinizing
hormone, E2, 17β estradiol, OAT, oligoasthenoteratozoospermia.
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thick film [Phenomenex, Torrance, CA, USA]). Briefly,
vials were heated at 55°C and kept at this temperature
for 30 min, to allow the volatile compounds to reach
equilibrium between the gaseous and aqueous phases.
Then the SPME device was inserted into the vial and
the fiber was exposed to the headspace above the sample
for 15 min. Analytes were thermally desorbed by insert-
ing fibers into the gas chromatography (GC) injector at
250°C. The GC oven temperature was kept at 50°C for
2 min, then the temperature was increased to 90°C at
6°C/min and maintained at 90°C for 1 min. Helium (pur-
ity: 99.5%) was used as carrier gas, at 1 ml/min constant
flow. The mass spectrometry (MS) detector (source
temperature, 200°C) was operated in the selected ion
monitoring mode. The acquired masses were 51.0, 77.0
and 78.0 m/z for benzene, and 82.2, 84.2 m/z for the in-
ternal standard.
Given the small amount of FF samples available, we
did not use the standard addition approach generally
adopted to quantify benzene in biological matrices. Ra-
ther we determined benzene concentration ([B]s) by
normalizing the benzene chromatographic peak area
(AreaBS) with respect to the internal standard area
(AreaIS) and with respect to the volume (V) of each sam-
ple. The following equation was used: [B]s = [(AreaBS ⋅
1.48 ng)/AreaIS]/V.
Statistical analysis
The primary study endpoint of this pilot study was the
change in the number oocytes retrieved. Secondary
endpoints were the mean number of gonadotrophin
vials used, the duration of COS, the mean number of
embryos transferred and the ongoing pregnancy rate.
The population study sample was determined arbitrar-
ily; we were unable to make a pre-study sample size
calculation because of the lack of similar studies on
this topic.
Results were analyzed using the statistical package
SPSS 12.0 for Windows (SPSS Inc., USA). We used the
D’Agostino-Pearson normality test to quantify the distri-
bution of all continuous variables. A one-way analysis of
variance (ANOVA) was used to determine the effects of
stimulation protocols on continuous variables. The
Mann–Whitney U test was used to assess inter-group
differences in relation to non-parametric continuous var-
iables and the χ2 test to compare discontinuous data.
We assessed the relationship between continuous vari-
ables and intra-follicular levels of benzene with a linear
correlation (Pearson’s correlation), whereas we used
Spearman’s coefficient to determine the relationship
between intra-follicular levels of benzene and non con-
tinuous variables. A p value < 0.05 was considered statis-
tically significant.Results
The demographic and hormonal characteristics and the
indications for IVF/ICSI of the study population are re-
ported in Table 1. Linear regression analysis showed that
the intra-follicular level of benzene was significantly and
positively correlated with baseline FSH level (r = 0.38;
p = 0.03). Furthermore, it was significantly and negatively
correlated with each of the following variables: average
number of oocytes retrieved (r = −0.43; p = 0.010) and
average number of embryos transferred (r = −0.37; p =
0.03). There was no correlation between benzene levels
and the following variables: baseline E2 (17β-estradiol)
levels (p = 0.38), baseline LH (luteinizing hormone)
levels (p = 0.16), E2 peak levels (p = 0.086), number of ex-
ogenous gonadotrophin vials used (p = 0.57) and number
of days of stimulation (p = 0.86).
To evaluate the effect of benzene, we divided the study
population into two groups using the median benzene
concentration (0.54 ng/mL) as cut-off value. Group A
(n = 19) had levels of intra-follicular benzene < 0.54 ng/mL
and Group B (n = 15) levels ≥0.54 ng/mL (data not
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did not differ between the two groups (Table 1). No differ-
ence regarding main indications to IVF/ICSI was found
between groups (data not shown).
There was no statistical difference in terms of baseline
LH, baseline E2, number of gonadotrophin vials used, and
number of days of stimulation between the two groups.
On the contrary, baseline FSH levels were higher in
group B than in group A (11.3 ± 4. 2 versus 5.8 ± 1.1; p =
0.003), and the E2 peak was significantly lower in group
B (1328.8 ± 493.0 versus 1836.65 ± 661.9; p = 0.008).
The number of oocytes retrieved (6.61 ± 2.85 versus
7.4 ± 2.5; p = 0.01) were lower in group B than in group
A. Although all women were considered eligible for em-
bryo transfer, the number of embryos transferred was
higher in group A, i.e., the group with a low intrafollicular
benzene concentration (2.3 ± 0.6 versus 2.6 ± 0.4; p = 0.04).
Finally, the ongoing pregnancy rate was comparable in
the two groups (Table 1). Specifically, we obtained four
singleton pregnancies in group A, and three singleton
pregnancies and one twin pregnancy in group B.
Based on the replies to the questionnaire, we looked
for variables that might account for the differences in
the intra-follicular benzene concentration between the
two groups. There was no significant difference in terms
of place of residence and occupational risk of benzene
exposure (data not shown). However, there was a differ-
ence, albeit not significant, regarding cigarette smoking
(26.3% in group A versus 40.0% in group B) and driving
habits (68.4% in group A and 46.65% in group B).
Discussion
This study provides the first evidence that high concen-
trations of benzene in the ovary can impact negatively
on gonadal function and on the ovarian response to en-
dogenous and exogenous gonadotrophin. In particular, a
significant correlation was found between intra-follicular
levels of benzene and FSH baseline. This correlation was
confirmed when the study population was divided into
two groups based on intra-follicular levels of benzene;
indeed, baseline FSH concentration was significantly
higher in patients with higher intra-follicular benzene
values (Group B). Also baseline LH level was higher in
group B, but the difference was not significant, probably
due to the population size.
Consistent with these observations, we also demon-
strate that benzene adversely affects ovarian response to
exogenous gonadotrophin during IVF procedures. In-
deed, there was a statistically significant inverse relation-
ship between the intra-follicular levels of benzene and
the average number of oocytes recovered and embryos
implanted. This observation was confirmed by the re-
sults obtained in the two groups: peak estradiol, average
number of oocytes recovered and average number ofembryos implanted were significantly higher in group A,
which was characterized by low levels of benzene.
Nevertheless, the number of gonadotropin vials and the
average duration of stimulation did not differ between
the two groups. These findings support the hypothesis
that benzene could lead to ovarian resistance to exogen-
ous gonadotrophin. Even though a slower and lower re-
sponse to r-hFSH occurred in the high benzene group,
oocyte retrieval was apparently satisfactory and the daily
dose of exogenous gonadotrophin was not increased in
the “high” benzene group. A possible explanation of this
discrepancy is that benzene exerted local toxicity on fol-
licles thereby affecting the number observed during scan
monitoring and, to a greater extent, their subsequent
maturation process. This discrepant effect could also be
related to the characteristics of the study population and
of course to the small number of patients enrolled in the
study. According to our findings, it seems that the normal
ovarian reserve probably counteracted the detrimental ef-
fects of benzene, leading to a sort of “hypo-response” ra-
ther than the classical “poor ovarian response” [23].
However, given the low number of patients evaluated, this
hypothesis needs to be verified in larger trials.
Our data are in accordance with observational studies
conducted in a business environment which revealed
that exposure to benzene can negatively affect reproduc-
tion function [24-26].
However, using the model of IVF/ICSI we show, for
the first time, that high intra-ovarian levels of benzene
are associated with hypo-sensitivity of follicles to go-
nadotrophin stimulation. The mechanism underlying
this phenomenon is not clear. We may speculate that
ovarian resistance results from an alteration of transduc-
tional efficiency of FSH receptor or that benzene exerts
a degenerative effect on follicles, thereby reducing the
follicular reserve.
If our findings are confirmed, the next step would be to
evaluate the ovarian reserve in patients with high intra-
ovarian levels of benzene by measuring circulating levels of
anti-Müllerian hormone and by counting the number an-
tral follicles in early follicular phase using trans-vaginal
standard and three dimension ultrasound [27,28]. In
addition, it would be interesting to evaluate older patients
to determine whether age affects benzene toxicity. Unfortu-
nately, we were unable to perform this analysis because of
the small subgroup of cases above the age of 35 years old.
Although the present study provides information only
about oocyte quantity during IVF, it could be argued that
altered sensitivity to FSH is associated with reduced oo-
cyte quality, which in turn could affect the chances of
pregnancy and the risk of abortion [29]. This issue
should be addressed in a prospective trial performed in a
larger IVF study population, with the pregnancy rate as
primary endpoint.
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tionnaire designed to explore the link between life-style
and concentration of benzene in the ovary. Currently,
there is no standardized questionnaire that reliably as-
sesses benzene assumption and driving habits. The reli-
ability of self-reports of smoking is often questioned due
to the underestimation of the smoking status recorded
especially in communities where this habit is perceived
as being particularly improper [30]. Despite this relevant
bias and a sample size too low to detect a statistically
significant correlation, our data suggest that high intra-
follicular levels of benzene are related to an at-risk life-
style, namely, cigarette smoking.
The aim of our study was to investigate the direct ef-
fect of follicular benzene on the outcome of COS. We
did not evaluate serum levels of the hydrocarbon mol-
ecule at that stage. Should our data be confirmed, the
next step would be to investigate the relationship between
serum and follicular concentration of benzene. This infor-
mation could shed light on the potential role of serum
levels of benzene in predicting ovarian response.Conclusion
Overall, the results of this study, although preliminary,
support the existence of a link between exposure to ben-
zene and reduced reproductive capacity, and provide evi-
dence of follicular hyposensitivity to FSH in women with
high gonadal concentrations of the molecule. The next
step would be to define the pathogenetic mechanisms
underlying resistance to endogenous gonadotrophin and
the reduced ovarian response to exogenous gonado-
trophin. Comparative analysis carried out in large popu-
lations using the in vitro fertilization model would
enable an accurate assessment of the effects of benzene
on each stage of the reproductive process.
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